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Transforming growth factor beta (TGFb) is a multipotent cytokine that is sequestered in the extra-
cellular matrix (ECM) through interactions with a number of ECM proteins. The ECM serves to con-
centrate latent TGFb at sites of intended function, to inﬂuence the bioavailability and/or function of
TGFb activators, and perhaps to regulate the intrinsic performance of cell surface effectors of TGFb
signal propagation. The downstream consequences of TGFb signaling cascades in turn provide feed-
back modulation of the ECM. This review covers recent examples of how genetic mutations in con-
stituents of the ECM or TGFb signaling cascade result in altered ECM homeostasis, cellular
performance and ultimately disease, with an emphasis on emerging therapeutic strategies that seek
to capitalize on this reﬁned mechanistic understanding.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The role of ECM in TGFb localization, sequestration and
activation
The transforming growth factor beta (TGFb) superfamily con-
sists of a number of cytokines that regulate diverse cellular func-
tions, including proliferation, differentiation, and synthesis of a
wide array of gene products. TGFb exists in at least three isoforms
(TGFb1–3), which are highly conserved. They are all synthesized
within cells as large protein precursors. Each has an N-terminal
signal peptide that is required to permit secretion from the cell, a
pro-region (latency associated peptide, LAP), and a C-terminal por-
tion that is cleaved from the pro-region to become the mature
TGFb molecule. Following cleavage within the cell, the mature
TGFb molecule remains non-covalently bound to the LAP as part
of the small latent complex (SLC). The SLC remains in the cell until
it is bound by one of four latent TGFb-binding proteins (LTBPs 1–4),
forming the large latent complex (LLC).
Following secretion from the cell, the LLC initially interacts via
LTBPs with ﬁbronectin ﬁbrils and heparin sulfate proteoglycans
at the cell membrane, and then subsequently relocates tochemical Societies. Published by E
ay, BRB 535, Baltimore, MD
e).ﬁbrillin-rich microﬁbrils in the extracellular matrix (ECM) [1,2].
LTBPs and ﬁbrillins belong to the same gene family. Both have
two types of repeating cysteine-rich domains, epidermal growth
factor (EGF)-like repeats, and the so-called eight-cysteine (8-cys)
or transforming growth factor protein-binding (TB) domains.
Fibrillins-1, -2 and -3 are large glycoproteins that are the major
components of microﬁbrils. Fibrillin-1 is the most prevalent post-
natal form, and is found in several elastic and non-elastic tissue
types, including the skin, vasculature, bones, lungs and eye. Incor-
poration of the LLC into microﬁbrils involves interaction between
LTBPs 1 and 4 and the N-terminus of ﬁbrillin-1 [3]. Activation of
TGFb occurs when free ligand is released from the microﬁbril-
bound LLC. Various modes of activation have been proposed,
including protease-mediated cleavage and integrin-mediated re-
lease, the latter of which appears to result from either mechanical
force transduction or metalloprotease-mediated release [4].
Following its release from the ECM, TGFb binds to its type II cell
surface receptor (TbRII), which recruits and phosphorylates the type
I receptor (TbRI). TbRI then recruits and phosphorylates a receptor
regulated SMAD (R-SMAD) protein, namely SMAD2 and/or SMAD3.
These R-SMADs then bind to the common SMAD (co-SMAD) SMAD4
to form a heterodimeric complex. This complex enters the cell
nucleus where it acts as a transcription factor for various
TGFb-dependent genes, such as connective tissue growth factor
(CTGF), plasminogen activator inhibitor-1 (PAI-1) and multiple
collagens.lsevier B.V. All rights reserved.
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Marfan syndrome (MFS) is an autosomal dominant systemic
connective tissue disorder that is primarily associated with mani-
festations in the cardiovascular, skeletal and ocular systems. More
speciﬁcally, it includes a strong predisposition for aortic root aneu-
rysm, with consequent vessel tear (dissection) or rupture, long
bone overgrowth and ocular lens dislocation (ectopia lentis; EL).
Other manifestations include mitral valve prolapse, spine curva-
ture (both scoliosis and kyphosis), chest wall deformity, spontane-
ous pneumothorax, dilation of the dural sac (dural ectasia), near-
sightedness (myopia) and skin stretch marks.
MFS is caused by mutations in the FBN1 gene, which encodes
ﬁbrillin-1. It was long thought that ﬁbrillin-1 containing microﬁ-
brils were required for elastic ﬁber formation (elastogenesis) with-
in the ECM. This led to the belief that individuals with MFS are
born with an obligate predisposition for tissue structural weakness
and ultimately failure. This was thought to explain why in MFS the
aorta dilates at blood pressures that would not typically have any
deleterious consequence. This boded poorly for the development of
novel therapeutic strategies for the disease. However, it was evi-
dent that certain manifestations of MFS, such as bone overgrowth,
mitral valve elongation and thickening, and skeletal muscle hypo-
plasia, were difﬁcult to reconcile with a pathogenic model that sin-
gularly invoked compromised tissue structural integrity; they were
more suggestive of altered cellular performance. The degree of
homology between the ﬁbrillins and LTBPs prompted the hypoth-
esis that perhaps abnormal or insufﬁcient ﬁbrillin-1 containing
microﬁbrils in the tissues of MFS patients might lead to altered
TGFb activation. Whether this was true, and whether TGFb was
driving disease pathogenesis in MFS, remained to be determined.
It was subsequently shown that mice heterozygous for a mis-
sense mutation in ﬁbrillin-1 (Fbn1C1039G/+; hereafter referred to as
MFS mice) show excess TGFb signaling, as evidenced by increased
Smad2/3 activation in the aortic root, lung, skeletal muscle and mi-
tral valve [5–8]. To prove that increased TGFb signaling was a dri-
ver rather than simply a marker or consequence of disease
progression, MFS mice were treated with systemic TGFb-neutraliz-
ing antibody (TGFb NAb). This led to rescue of the aortic, lung, skel-
etal muscle and mitral valve phenotypes in the mice, in association
with blunted Smad2/3 activation.
The angiotensin II (ANG-II) type 1 receptor (AT1R) blocker (ARB)
losartan is a clinically-available blood pressure lowering agent that
had been shown to attenuate TGFb signaling in certain disease
states, such as chronic renal failure, by reducing the expression
of TGFb ligands, [9] receptors, [10,11] and activators [12]. Given
its ability to inhibit TGFb signaling in other disease states, as well
as the fact that lowering blood pressure is a desirable effect in MFS,
a trial of losartan was performed in MFS mice. Losartan treatment
led to a signiﬁcant rescue of aortic root aneurysm progression, aor-
tic wall thickness and aortic wall architecture in MFS mice, com-
pared to treatment with either placebo or a hemodynamically-
equivalent dose of the b-blocker propranolol [5]. A similar pheno-
typic rescue with losartan was also observed in the lungs and skel-
etal muscle of MFS mice, tissues in which blood pressure changes
would have no inferred relevance. Notably, rescue in all tissues
correlated with a reduction in Smad2/3 activation, suggesting that
losartan was achieving its therapeutic effect through antagonism
of TGFb signaling [5].
There is preliminary evidence to suggest that these ﬁndings
hold promise for patients with MFS. The effect of ARBs was as-
sessed in a small cohort of pediatric MFS patients who had severe
aortic root enlargement despite previous alternative medical ther-
apy. This study found that ARBs signiﬁcantly slowed the rate of
aortic root and sinotubular junction dilatation, whereas the distalascending aorta (which does not normally become dilated in
MFS) remained unaffected [13]. In light of this growing body of evi-
dence, several multi-center prospective clinical trials to assess the
therapeutic potential of ARBs in MFS are underway [14]. It also
appears that circulating TGFb blood levels may represent a novel
biomarker for aneurysm progression and response to therapy in
MFS [15]. Circulating total Tgfb1 concentration is elevated in older
untreated MFS mice compared to wild type (WT) littermates. Fur-
thermore, losartan treatment of MFS mice leads to lower total
Tgfb1 concentration compared with age-matched placebo-treated
littermates, to levels indistinguishable from age-matchedWTmice.
In humans, circulating total TGFb1 concentration is elevated in pa-
tients with MFS compared to controls, while MFS patients treated
with losartan or b-blocker show signiﬁcantly lower circulating
TGFb1 concentration compared with untreated patients.
3. Intracellular TGFb-dependent signaling cascades driving
aneurysmal disease in MFS
Following aberrant matrix-dependent activation of TGFb and
subsequent interaction with its cell surface receptor, it remained
to be determined what the critical TGFb-dependent intracellular
mediators were driving disease pathogenesis in MFS. Until re-
cently, much of the focus in both MFS and other TGFb-dependent
disease states had been placed on so-called canonical (i.e. SMAD-
dependent) pathways. However it was becoming increasingly
recognized that TGFb can also stimulate other (non-canonical) cas-
cades, including the phosphatidylinositol-3-OH kinase (PI3 K)/AKT,
Rho-associated protein kinase (ROCK), and mitogen-activated
protein kinase (MAPK) cascades, the latter of which includes extra-
cellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK)
and p38 [16]. While Smad2/3 activation had been shown to corre-
late with both disease progression and therapeutic rescue by TGFb
NAb and losartan in MFS mice, a cause-and-effect relationship had
yet to be determined.
Western blot analysis indicated that both Smad2 and Erk1/2 are
activated in the proximal ascending aortas of MFS mice, and both
are inhibited by TGFb NAb and losartan [17]. This increase in
Smad2 and Erk1/2 activation occurs selectively in portions of the
aorta affected in MFS mice, since no such activation was seen in
the descending thoracic aorta [18]. Furthermore, selective inhibi-
tion of Erk1/2 activation using the orally-bioavailable MEK1 inhib-
itor RDEA119 led to complete abrogation of abnormal aortic root
growth in MFS mice. Erk1/2 activation, but not Smad2 activation,
was reduced in RDEA119-treated MFS animals, conﬁrming the
speciﬁcity of the drug and illustrating that Smad2 activation in
MFS mice is not Erk-dependent. Furthermore, RDEA119 had no
effect on aortic root growth in WT mice, indicating that it selec-
tively targets MFS-associated pathological aortic growth, rather
than simply inducing aortic hypoplasia. This suggests that the
non-canonical TGFb-dependent Erk1/2 cascade plays a critical role
in aortic disease progression in MFS mice.
There is considerable evidence in the literature linking the TGFb
and angiotensin signaling pathways. It is well recognized that
ANG-II can mediate progression of aortic aneurysm, but the rela-
tive contributions of the AT1R and the angiotensin-II type 2 recep-
tor (AT2R) remained unknown in MFS. Given losartan’s therapeutic
efﬁcacy via inhibition of the AT1R, this receptor appeared likely to
play a role in disease pathogenesis in MFS. The contribution of the
AT2R to aortic aneurysm progression in MFS remained controver-
sial. On the one hand, AT2R signaling has been shown to oppose
AT1R-mediated enhancement of TGFb signaling in some cell types
and tissues, [19] which would suggest it should provide protection.
In contrast, AT2R signaling can also induce vascular smooth muscle
cell (VSMC) apoptosis, theoretically contributing to aortic wall
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question the relative therapeutic merits of selective AT1R blockade
with ARBs versus limiting signaling through both the AT1R and the
AT2R using angiotensin-converting enzyme inhibitors (ACEi) that
prevent production of ANG-II.
Genetic elimination of At2r was shown to accelerate aortic
growth and rupture in MFS mice, indicating that AT2R signaling
provides protection within this context [21]. Furthermore, losar-
tan’s efﬁcacy is reduced in At2r-deﬁcient MFS mice, indicating that
ARBs achieve their effect, at least in part, through selective AT1R
blockade, which could stimulate signaling through the AT2R. To di-
rectly assess the efﬁcacy of ARBs versus ACEi, a head-to-head trial
of hemodynamically-equivalent doses of the ARB losartan and the
ACEi enalapril was performed in MFS mice. Enalapril was less
effective than losartan in reducing aortic root growth. Both agents
attenuated canonical TGFb (i.e. Smad2) signaling in the aortas of
MFS mice, but losartan uniquely inhibited Erk1/2 activation.
Although concordant effects of prior therapies on canonical and
non-canonical TGFb signaling cascades made it impossible to dis-
sect out their relative contributions, the differential effects of losar-
tan and enalapril suggest that non-canonical TGFb signaling
(speciﬁcally Erk1/2), is the predominant driver of aneurysm pro-
gression in MFS mice.
There is evidence in patients with MFS that ACEi therapy may
be beneﬁcial. Enalapril treatment was shown in a small cohort of
MFS patients to be favorable over b-blocker therapy, [22] although
no biochemical analysis was performed and no comparison to ARBs
was made. Another study suggested that treatment with the ACEi
perindopril is beneﬁcial in patients with MFS, [23] although the
analysis period was relatively brief (six months), ACEi therapy
was not prescribed in isolation (but rather was used in combina-
tion with b-blockers), and no comparison to ARBs was made. How-
ever, the study did show that combined ACEi/b-blocker therapy led
to a signiﬁcant reduction in circulating latent and active TGFb, as
well as total matrix metalloproteinase (MMP)-2 and -3 levels.
Hence it remains unclear what the relative therapeutic merits of
ARBs versus ACEi are in patients with MFS, an issue that is further
clouded by the fact that some ACEi such as perindopril may have a
number of pleitropic effects.
It is also possible that other non-canonical TGFb signaling cas-
cades contribute to aortic disease in MFS. On the one hand, no evi-
dence for increased Jnk, p38 or RhoA activation has been observed
in the aortas of Fbn1C1039G/+MFS mice. [17] Furthermore, an in vivo
trial of fasudil, a well-established inhibitor of the RhoA/Rock path-
way, failed to attenuate aortic root growth in these animals. How-
ever, Smad4 haploinsufﬁciency was found to exacerbate aortic
disease and cause premature lethality in MFS mice, in association
with enhanced Jnk activation, while a Jnk antagonist ameliorated
aortic growth in MFS mice that either lacked or retained full Smad4
expression. This suggests that manipulation of Smad-dependent
TGFb signaling cascades (e.g. Smad4 haploinsufﬁciency) can di-
rectly or indirectly activate non-canonical signaling cascades (e.g.
Jnk), and that Jnk inhibition may be another potential therapeutic
strategy for MFS. This observation is consistent with prior work
showing that Jnk1 inhibition can ameliorate abdominal aortic
aneurysm (AAA) induced by the periaortic application of calcium
chloride [24].
There is some evidence that the p38 MAPK cascade may be in-
creased in ﬁbrillin-1 null states [25]. In vitro elimination of ﬁbril-
lin-1 deposition has been shown to result in activation of Smad2,
p38 and its upstream activator TGFb-activated kinase 1 (Tak1).
Furthermore, Western blot analysis of the aortic wall in ﬁbrillin-
1 null (Fbn1MgN/MgN) mice shows increased Smad2 and p38 activa-
tion relative to WT animals, although it remains to be seen
whether selective p38 inhibition inﬂuences aortic disease progres-
sion in these animals. Furthermore, it is yet to be determined whyin the aortas of mice haploinsufﬁcient for a missense mutation in
FBN1 (i.e. Fbn1C1039G/+), selective Erk1/2 and Smad2 activation oc-
curs, with Smad2 activation being Erk1/2-independent; yet in the
aortas of mice null for ﬁbrillin-1 (i.e. Fbn1MgN/MgN), selective p38
and Smad2 activation occurs, with Smad2 activation perhaps being
partially p38-dependent. Whether these differences relate to the
animal models used, the timing of the analyses or some other as-
pect of TGFb signaling is not yet known.
Aortic aneurysm also occurs in human conditions known to
modify RAS signaling, a major upstream activator of ERK1/2. These
include gain-of-function mutations in the PTPN11 gene (encoding
the protein tyrosine phosphatase SHP2) which causes Noonan syn-
drome, and loss-of-function mutations in the NF1 gene (encoding a
RAS GTPase-activating protein) which causes neuroﬁbromatosis
Type 1. In mouse models of Noonan syndrome, multiple manifesta-
tions of the disease, including cardiac, craniofacial and heart valve
deformities have been shown to be Erk-dependent (reviewed in
[26]). While the vast majority of individuals with MFS show aortic
aneurysm, this phenotype is of low penetrance in Noonan syn-
drome or NF Type 1. One explanation for this may be that PTPN11
or NF1 are not highly expressed, or are of minor signiﬁcance to
ERK1/2 signaling, in the human aorta. Another possibility is that
ERK1/2 activation alone is not sufﬁcient for aneurysm to develop;
while there is overlap in the intracellular cascades activated in MFS
and Noonan syndrome mice (Erk1/2), other pathways appear to be
MFS-speciﬁc (Smad2/3, p38 and possibly Jnk). Furthermore, in
mouse models Erk1/2 activation appears to be TGFb-dependent
in MFS but may be TGFb-independent in Noonan syndrome.
Whether it is the nature or number of intracellular signaling path-
ways involved, the manner by which they are activated, their de-
gree of activation (which itself may be magnitude- or threshold-
based), the relative balance of different signaling pathways (e.g.
Smad and Erk1/2 cascades), or some other variable, is yet to be
determined.4. Activation of TGFb-dependent signaling cascades causes
feedback modulation of the ECM
There are a number of downstream targets of TGFb signaling,
which can provide feedback modulation of the ECM, either directly
through the deposition of gene products or indirectly through their
inﬂuence on existing ECM components. TGFb-dependent increases
in CTGF, PAI-1 and collagen expression are well documented in the
aorta and other tissues in patients with MFS. Another group of ECM
proteins that have received much attention in MFS are MMPs. Both
Mmp2 and Mmp9 have been shown to be upregulated in the aorta
of MFS mice [27,28]. Furthermore, doxycycline, a non-speciﬁc
MMP inhibitor, has been shown to attenuate elastic ﬁber degener-
ation and improve vasomotor function in the aorta of MFS mice.
This was in association with augmented tissue inhibitors of Mmp
(Timp2/9) to Mmp2/9 ratio and suppression of TGFb in the aortas
of these mice [27]. Doxycycline has also been shown to reduce
the rate of aortic dissection and improve survival in a more severe
mouse model of MFS (Fbn1MgR/MgR), in association with reduced
Mmp2 and 9 expression [28]. Given that losartan has also been
shown to reduce Mmp2 and Mmp9 expression and activation in
the aortas of MFS mice, [29] a trial assessing the therapeutic
potential of combined doxycycline and losartan treatment was
performed. In comparison to the two agents used in isolation, com-
bination therapy led to a greater rescue of aortic diameter and aor-
tic wall architecture [30].
There is substantial evidence linking TGFb, ERK1/2 and MMP
activity. ERK1/2 has been shown to increase MMP9 expression in
cultured aortic smooth muscle cells, while selective inhibition of
ERK1/2 activation reduces this expression [31]. MMP2 and MMP9
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hinge region of the LAP complex being an obvious potential target
for their activity. Furthermore, both MMP2 and MMP9, as well as
other MMPs, have been shown to mediate ANG-II dependent trans-
activation of the epidermal growth factor receptor (EGFR) and con-
sequent ERK1/2 activation in vascular cells [32]. This suggests that
a feed-forward loop could develop in MFS, whereby increased
TGFb-dependent ERK1/2 activation drives MMP2/9 expression
and/or activation; MMP2/9 could in turn augment TGFb activation
and/or ANG-II mediated EGFR-transactivation, leading to enhanced
or prolonged canonical or non-canonical TGFb signaling. Given the
permissive role of ANG-II in this process, it raises the possibility
that the efﬁcacy of ARBs in MFS may at least in part derive from
their ability to intervene in this potentially detrimental feed-for-
ward loop.
Erk1/2 activation has also been shown to mediate Ang-II infu-
sion driven AAA formation in apolipoprotein E-knockout mice
through the modulation of Mmp2/9. Furthermore, selective inhibi-
tion of Erk1/2 activation using CI1040, or treatment with the
HMGCoA reductase inhibitor simvastatin, led to amelioration of
AAA progression in this disease model, in association with reduced
Erk1/2 and Mmp2/9 activation [33]. In light of this, the potentialFig. 1. Integrated signaling cascades in Marfan syndrome and related diseases. Canonica
proteins not currently implicated in downstream TGFb signaling (red), are illustrated acc
the protein. Drugs shown in green have been tested in Marfan mice and/or patients. Dru
understanding of disease pathogenesis. MFS: Marfan syndrome; SSS: Stiff skin syndrome
dysplasia; AC: Acromelic dysplasia; HHT T1: Hereditary hemorrhagic telangiectasia Type
syndrome; PVNH: Periventricular nodular heterotopia; LDS: Loeys Dietz syndrome; iFTA
neutralizing antibody; ARB: Angiotensin II Type 1 receptor blocker (e.g. losartan); ACEi:therapeutic efﬁcacy of HMGCoA reductase inhibitors was assessed
in MFS mice. Compared to placebo-treated MFS animals, simvasta-
tin-treated mice showed a signiﬁcant reduction in aortic root size
and signiﬁcantly greater elastic ﬁber preservation [34]. Since no
biochemical analysis was performed, it remains to be deter-
mined whether the effects of simvastatin therapy in MFS mice
are TGFb-, Erk1/2- and/or Mmp2/9-related. An integrated model
of our current understanding of the molecular mechanisms driving
disease pathogenesis in MFS is illustrated in Fig. 1.
5. Mutations in FBN1 cause TGFb-dependent phenotypes
distinct from MFS
As well as causing MFS, mutations in FBN1 can cause a number
of other disorders, including stiff skin syndrome (SSS). SSS is a rare
autosomal dominant ﬁbrillinopathy characterized by thickened ﬁ-
brotic skin throughout the entire body that is present at birth, as
well as secondary joint contractures. Patients are also shorter than
normal, with a mean adult male and female height of < 15th
and < 5th percentile, respectively. Other occasional features in-
clude diffuse entrapment neuropathy (nerve injury and dysfunc-
tion because of local compression), focal lipodystrophy, musclel (green) and non-canonical (blue) TGFb signaling cascades, as well as intracellular
ordingly. Disorders caused by a mutated gene product are shown in brackets next to
gs shown in red are untested but may have hypothetical beneﬁt, based on current
; WMS: Weill-Marchesani syndrome; ELS: Ectopia lentis syndrome; GD: Geophysic
1; HHT T2: Hereditary hemorrhagic telangiectasia Type 2; ATS: Arterial tortuosity
A: Isolated familial thoracic aortic aneurysm; FSS: Ferguson Smith syndrome. NAb:
Angiotensin-converting enzyme inhibitor (e.g. enalapril).
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interphalangeal joints. Approximately 40 cases have been docu-
mented; one report identiﬁed 4 families with dominant SSS caused
by heterozygous missense mutations in exon 38 of FBN1 that either
create or destroy cysteine residues within the N-terminal portion
of the fourth 8-cysteine domain (TB4). Interestingly, one patient
who presented with both EL and SSS, which is more suggestive
of an overlap phenotype between SSS and MFS, was found to pos-
sess a de novo mutation downstream in exon 39 of FBN1 [35].
Relative to control skin, SSS skin has a widened zone of dense
collagen, an excess of both ﬁbrillin-1 and elastin throughout the
dermis, excessive and disorganized microﬁbrillar aggregates, and
patchy elastin distribution. Evidence for aberrant TGFb signaling
has been seen in dermal biopsies from SSS patients, including nu-
clear accumulation of phosphorylated SMAD2 and increased
expression of collagen and CTGF [35].
The phenotypic diversity of TGFb-associated ﬁbrillinopathies
suggests that the effect of microﬁbrils on TGFb regulation is com-
plex. Data derived from mouse models of MFS have shown that
microﬁbrils can limit TGFb activation via binding to the LLC. In con-
trast, evidence from other mouse models suggests that microﬁbrils
can enhance TGFb signaling in certain contexts, by concentrating
the cytokine at sites of intended function. Mutations in FBN2 cause
autosomal dominant congenital contractural arachnodactyly (CCA
or Beals syndrome), which is characterized by kyphoscoliosis, oste-
openia, joint contracture and arachnodactyly. CCA mouse models
deﬁcient in ﬁbrillin-2 do not show contractures, but instead show
syndactyly. Genetic studies showed this to be a result of decreased
local concentration of, and activity by, the TGFb superfamily mem-
ber bone morphogenetic protein 7 (Bmp-7) in the developing auto-
pod [36]. Extrapolating from these data, it has been posited that
microﬁbrils may help concentrate the LLC in a tissue-speciﬁc man-
ner, thereby localizing TGFb and its consequent signaling to spe-
ciﬁc sites of action. In this way, the level of TGFb signaling in a
given tissue may, at least in part, be determined by both positive
and negative regulation by microﬁbrils. This could explain why
the increased TGFb signaling that occurs in both MFS and SSS can
generate distinct phenotypes. In MFS, microﬁbrillar deﬁciency
may drop below a critical threshold, beyond which a decreased
concentration of the LLC in affected tissues (such as the aortic wall)
may be offset by a dramatic increase in TGFb activation. In con-
trast, increased microﬁbril accumulation in the skin of SSS patients
may lead to excess LLC recruitment to the skin; this could lead to
an inappropriately high concentration of latent TGFb within the
skin, which over time may result in chronically increased TGFb sig-
naling, ﬁbrosis and ultimately stiffening of the dermis [37].
6. Cell surface integrins mediate cell–ECM interactions and
inﬂuence TGFb signaling
The highly focal repertoire of FBN1 mutations that cause SSS
points to another possible role for microﬁbrils in TGFb regulation.
Mutations that cause MFS are found throughout the FBN1 gene. By
contrast, FBN1 mutations causing SSS cluster in the TB4 domain.
TB4 is the only domain that harbors an RGD motif, through which
ﬁbrillin-1 binds cell-surface receptors known as integrins. This im-
plies that impaired integrin–ECM interaction may contribute to SSS
pathogenesis. For example, if ﬁbrillin-1 is a critical informant of
ECM status for cells, and it signals this information via integrins,
then perturbation of this mechanism may initiate a cascade of
compensatory cellular events, leading to excess ECM production.
In keeping with this hypothesis, cells expressing integrins avb3
and a5b1 plated on recombinant ﬁbrillin-1 fragments bearing
SSS mutations show a dramatically reduced ability to support inte-
grin-mediated events, including cell attachment and spreading.
More recent evidence suggests that SSS dermal cells respond toaberrant integrin–ECM interaction with compensatory changes in
integrin expression and localization, altered responses to cytokines
such as TGFb, and increased ECM production, culminating in skin
ﬁbrosis (Dietz, unpublished; Fig. 2).
Studies of SSS-related ﬁbrotic diseases also implicate altered
integrin–ECM interaction in pathogenic TGFb regulation. For exam-
ple, altered integrin signaling has been implicated in the most
commonly recognized form of acquired skin ﬁbrosis, namely sys-
temic sclerosis (SSc). SSc is characterized by excess ECM deposition
in the skin, with additional features including autoantibody pro-
duction, peripheral vasoconstriction, and ﬁbrosis of other organs
such as the kidney, heart and lungs. The excess ECM deposition
in the SSc dermis is predominately composed of collagen, but also
includes ﬁbronectin and excess microﬁbril accumulation [38,39].
Evidence for increased TGFb signaling in SSc includes increased
activation of SMAD2 in the SSc dermis and in vitro dermal ﬁbro-
blast culture, as well as increased expression of TGFb-responsive
genes in skin biopsies from a subset of SSc patients with severe
skin ﬁbrosis [40]. SSc ﬁbroblasts have been shown to display atyp-
ical integrin presentation in vitro, [41,42] including the upregula-
tion of integrin avb3, while administration of avb3-neutralizing
antibody can inhibit avb3-dependent TGFb activation and TGFb-
dependent collagen production [43]. This and other work has di-
rectly implicated integrin-mediated TGFb activation in SSc and
other ﬁbrotic disorders [44,45].
The cells responsible for increased TGFb activation and excess
ECM production in SSc and other ﬁbrotic diseases are believed to
be myoﬁbroblasts. These arise from ﬁbroblasts or other cell types
such as epithelial or endothelial cells, which acquire smooth mus-
cle characteristics, including contractile stress ﬁbers and expres-
sion of a-smooth muscle actin (aSMA), through TGFb-mediated
mesenchymal transition [46,47]. When myoﬁbroblasts contract,
speciﬁc integrins at their cell surface mechanically pull the LAP,
thus releasing and activating TGFb from the LLC. Active TGFb then
drives ECM deposition, which in turn promotes myoﬁbroblast con-
traction via integrins bound to the stiffened ECM. In addition, TGFb
activation, ECM remodeling and decreased ECM compliance all
promote the differentiation of new myoﬁbroblasts [48]. Hence in
this context, stiffened ECM may serve to perpetuate myoﬁbroblast
contraction and excessive TGFb signaling.
Integrins have also been shown to modulate intracellular sig-
naling responses to a number of cytokines, including CCN2, [49]
VEGF, [50,51] IGF, [52] PDGF [53] and TGFb [49]. Proposed mecha-
nisms by which altered ligand–integrin interactions affect these
pathways include: (1) transcriptional or post-transcriptional
induction of integrin and/or growth factor expression; (2) en-
hanced trafﬁcking of integrins to the cell surface or recruitment
to active focal adhesions; (3) altered selection of or afﬁnity for inte-
grin–ligand binding; and (4) altered levels of active integrins at the
cell surface [54,55]. For example, loss of b1-integrin in cultured re-
nal tubular cells has been shown to promote avb3 integrin recruit-
ment to focal adhesions, its subsequent transactivation and
resultant TGFb-induced collagen expression. Critical steps in this
process include avb3-dependent activation of both Rac1 and ERK
[56]. There is also evidence that avb3 integrin directly interacts
with TbRII, [57] or with other secreted factors such as CCN2 that
associate with the TGFb receptor. In light of these data, it seems
feasible that altered integrin signaling may drive, or at least con-
tribute to, some or all of the aforementioned TGFb-dependent phe-
notypes, such as MFS-associated aortic disease, although this
remains to be demonstrated.
There is evidence that ECM proteins other than ﬁbrillin-1 may
also serve as informants to cells of ECM status via their interaction
with integrins (Fig. 2) [58]. Although the speciﬁc mechanism is un-
known, the ECM protein ﬁbronectin has also been implicated in
ﬁbrosis. For example, selective genetic deletion of ﬁbronectin in
Fig. 2. Extracellular matrix proteins inﬂuencing TGFb and other pathways in disease. Disorders caused by a mutated gene product are shown in brackets next to the protein.
Cells sense stiffened matrix through integrin-mediated bridging of ECM proteins (e.g. ﬁbrillins, ﬁbronectin, and collagens) to the cytoskeleletal proteins such as actin and
myosin. Integrins can also modulate intracellular signaling via interactions with growth factor receptors (e.g. VEGFR, PDGFR, and IGFR). Diseases: MFS: Marfan syndrome;
SSS: Stiff skin syndrome; WMS: Weill-Marchesani syndrome; ELS: Ectopia lentis syndrome; GD: Geophysic dysplasia; AC: Acromelic dysplasia; CL: Cutis Laxa, EDS: Ehlers
Danlos syndrome; URD: Urban–Rifkin–Davis syndrome. ⁄Hypothetical.
2008 J.J. Doyle et al. / FEBS Letters 586 (2012) 2003–2015the liver of mice results in increased collagen production and an
enhanced ﬁbrotic response to dimethylnitrosamine [59]. Further-
more, ﬁbronectin splice variant extra-domain-A (ED-A) is thought
to upregulate integrin-mediated signaling and myoﬁbroblast dif-
ferentiation, and has been implicated in ﬁbrosis of the liver, [60]
lungs [61] and retina [62].
7. Mutations in cell surface TGFb receptors have phenotypic
overlap with MFS
Mutations in TGFbRI and TGFbRII, which encode the TGFb recep-
tor subunits TbRI (ALK5) and TbRII respectively, result in disease
states that have clear phenotypic overlap with MFS, including
Loeys-Dietz syndrome (LDS) and isolated familial thoracic aortic
aneurysm (iFTAA).
Similar to MFS, patients with LDS typically show aortic aneu-
rysm, mitral valve prolapse, skeletal changes (long ﬁngers, chest
wall deformity), dural ectasia and skin stretch marks. By contrast,
they do not typically possess the lens dislocation seen in MFS, and
they can showmany unique features such as highly penetrant arte-
rial tortuosity, widely spaced eyes (hypertelorism), cleft palate or
biﬁd uvula, cervical spine malformation or instability, osteoporosis
and club foot deformity [63]. Most importantly, the vascular dis-
ease observed in LDS is more diffuse and aggressive than is typi-
cally seen in MFS; patients have a strong predisposition for
aneurysm and dissection throughout the arterial tree, with aortic
rupture typically occurring at younger ages and at smaller aneu-
rysm dimensions than in MFS [64]. Nearly all LDS patients harbor
heterozygous missense substitutions in the kinase domain of
TGFbRI or TGFbRII. Recombinant expression of mutant receptor
subunits in cells naïve for the corresponding subunit failed to sup-
port TGFb signaling, leading to the suggestion that disease mani-
festations result from decreased TGFb signaling [65]. This seemed
surprising, as it suggests that the concordant phenotypic manifes-
tations betweenMFS and LDS are caused by directly opposing TGFb
signaling states, namely high TGFb signaling in the former and low
TGFb signaling in the latter.
However, there is evidence to suggest that haploinsufﬁciency
is not the mechanism by which the LDS phenotype arises.
Firstly, haploinsufﬁciency for TbRI is already known to causeFerguson-Smith syndrome, a condition characterized by multiple
self-resolving squamous epitheliomas, but no phenotypic manifes-
tations of LDS. LDS patients have no evidence of any such lesions.
Furthermore, there have been no deletion or early nonsense muta-
tions identiﬁed in LDS patients thus far, either of which would have
favored haploinsufﬁciency as the causal mechanism. Instead,
mutant receptors causing LDS are synthesized, transported to the
cell surface and able to interact with TGFb ligand. What happens
after that remains less clear. Co-transfection studies in human cells
using equimolar concentrations of normal and mutant receptors,
as well as analysis of heterozygous patient cell lines have shown
signaling activity of WT receptor subunits to be normal, excluding
a conventional dominant-negative mechanism of action.
Interestingly, vascular tissue obtained at surgery or autopsy
from LDS patients has consistently shown an apparent paradoxical
increase in canonical TGFb signaling, as evidenced by increased
SMAD2 activation, and increased CTGF and collagen expression.
The mechanisms underlying this paradoxical effect are yet to be re-
solved, but may include altered receptor trafﬁcking, impaired auto-
regulation of TGFb signaling, and/or aberrant cell autonomous
signaling (reviewed in [66]). Another explanation may be that
TGFb-mediated activation of the canonical and non-canonical
cascades relies on separate portions of the TbRI/RII complex.
Distinct receptor kinase activities have been shown to drive the
phosphorylation of SMAD proteins and the ShcA adaptor protein
(an upstream mediator of ERK1/2 activation) [67]. Alternatively,
canonical and non-canonical TGFb-dependent pathways may be
activated through different processes. For example, while TGFb-
dependent SMAD activation occurs via receptor kinase mediated-
phosphorylation (which may be affected in LDS), there is evidence
that TGFb-dependent activation of some MAPKs occurs via ubiqui-
tylation of the TRAF6 ubiquitin ligase [68].
Mutations in TGFbRII (and occasionally TGFbRI) have also been
shown to cause iFTAA [69]. Analogous to the mutations causing
LDS, most of the mutations causing iFTAA identiﬁed to date have
been in close approximation in the intracellular domains of the
receptors, including the serine/threonine domain that is involved
in intracellular signal transduction. It seems notable that all muta-
tions associated with iFTAA have also been observed in patients
with classic LDS, suggesting that phenotypic variability may relate
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Downstream mediators of the canonical TGFb cascade have re-
cently been shown to cause phenotypes with considerable overlap
to LDS. Mutations in the SMAD3 gene have been associated with
aneurysms, dissections and tortuosity throughout the arterial tree,
in association with craniofacial (hypertelorism, cleft palate, biﬁd
uvula), skeletal and cutaneous anomalies, as well as early-onset
osteoarthritis [70]. Analogous to the aforementioned ﬁndings with
TGFbRI and TGFbRIImutations in LDS, the authors found that muta-
tions in SMAD3 lead to a paradoxical increase in aortic expression
of several key players in the TGFb pathway, including TGFb1 and
SMAD3 itself, increased output of TGFb-dependent gene products
such as CTGF and collagen, and direct evidence of increased TGFb
signaling (i.e. SMAD2 activation). Mutations in SMAD3 have since
been described in ﬁve families possessing iFTAA, one of which also
possessed intracranial and abdominal aortic aneurysms, but none
of which displayed osteoarthritis [71]. No analysis was made of
TGFb signaling in the tissues of these patients. Recently a nonsense
mutation in SMAD4 was identiﬁed in an individual whose family
history was positive for aortopathy, in association with mitral
valve disease and juvenile polyposis syndrome, [72] although again
no analysis of TGFb signaling status was performed. As with muta-
tions in TGFbRI and TGFbRII, the basis for paradoxical enhancement
of TGFb signaling remains to be elucidated.
8. Mutations in other ECM components result in altered TGFb
signaling
The ﬁbulins are a family of proteins thought to function as
intermolecular bridges within the ECM. Both ﬁbulin-4 and ﬁbu-
lin-5 bind to ﬁbrillin-1 and elastin, and play a role in elastic ﬁber
assembly and function (Fig. 2). While ﬁbulin-5 appears to promote
elastin ﬁber assembly through the recruitment of tropoelastin to
microﬁbrils, ﬁbulin-4 leads to the recruitment of lysyl oxidase
(LOX), which crosslinks elastin molecules [73]. In terms of disease
states, deﬁciency of ﬁbulin-4 causes autosomal recessive cutis laxa
in association with arterial tortuosity and aortic aneurysm in both
humans and mice, [74,75] while ﬁbulin-5 deﬁciency causes cutis
laxa with arterial tortuosity but not aneurysm. Evidence for in-
creased canonical TGFb signaling has been found in both humans
and mice deﬁcient in ﬁbulin-4. Increased SMAD2 activation and
CTGF expression were observed in the aortas and lungs of patients
harboring mutations in the gene encoding ﬁbulin-4 (EFEMP2), [76]
while analysis of aortic tissue from mice heterozygous or homozy-
gous for a ﬁbulin-4 hypomorphic allele revealed a graded increase
in Smad2 activation and nuclear translocation, Ctgf expression and
collagen deposition compared to WT animals [77]. As with MFS
mice, it appears that non-canonical TGFb signaling cascades, spe-
ciﬁcally the Erk1/2 pathway, are also activated in the aortas of mice
that are either globally- or smooth muscle cell selectively-deﬁcient
in ﬁbulin-4. An increase in Mmp9 expression has also been ob-
served in ﬁbulin-4 deﬁcient mice, although the potential therapeu-
tic beneﬁt of doxycycline and/or other MMP inhibitors are yet to be
determined in this mouse model.
Given the apparent upregulation of both TGFb signaling and
Ang-II in tissues of ﬁbulin-4 deﬁcient mice, the effect of ARB ther-
apy was assessed in these animals [78]. Prenatal losartan treat-
ment prevented elastic ﬁber fragmentation in the aortic media of
newborn homozygous targeted ﬁbulin-4 deﬁcient mice, while
b-blocker therapy showed no beneﬁcial effect on this parameter.
By contrast, postnatal losartan treatment reduced hemodynamic
stress and improved the lifespan of the animals, but did not ame-
liorate aortic architecture and failed to show a reduction in Smad2
activation. This suggests that in the context of ﬁbulin-4 associated
aneurysmal disease, ARBs can prevent aortic medial degeneration,but do not reverse pre-existing disease. The exact mechanism by
which ﬁbulin-4 deﬁciency leads to increased TGFb activation re-
mains to be determined. Failure of abnormal or absent ﬁbulin-4
to recruit LOX, which can directly inactivate TGFb ligand, [79] is
one possible mechanism, although this is yet to be shown
in vivo. Why ARBs show less postnatal beneﬁt in ﬁbulin-4 deﬁcient
mice than in MFS mice is unknown, although this could conceiv-
ably relate to the differing roles of ﬁbulin-4 and ﬁbrillin-1 in elastic
ﬁber formation and maintenance. Finally, why ﬁbulin-4 deﬁcient
mice display upregulated BMP signaling (in the form of increased
Smad1/5/8 activation) yet MFS mice do not, also remains
unanswered.
LTBPs 1, 3 and perhaps 4 are ECM components that appear to be
involved in the secretion and targeting of TGFb to sites at which it
is stored and/or activated. They may also exert effects independent
of those associated with TGFb, for example as structural proteins.
Human LTBPs 1, 2 and 4 also contain an Arg-Gly-Asp (RGD) se-
quence that potentially promotes interaction with cell mem-
brane-bound integrins. Mutations in LTBP4 have been associated
with cutis laxa in association with severe pulmonary, gastrointes-
tinal and urinary abnormalities (Urban–Rifkin–Davis syndrome)
[80]. Similarly, mice lacking Ltbp4 develop severe pulmonary
emphysema, cardiomyopathy and colorectal cancer [81]. These
highly tissue-speciﬁc abnormalities are associated with a lack of
Ltbp4 deposition in the ECM, profound defects in elastic ﬁber
structure and increased TGFb activity in cultured ﬁbroblasts. Muta-
tions in LTBP2 have been shown to cause primary congenital glau-
coma (PCG), [82] as well as an abnormally small ocular lens
(microspherophakia), while mutations in LTBP3 have been associ-
ated with an absence of many permanent teeth and an apparent in-
crease in bone density in the spine and skull base [83]. To date, no
human diseases have been associated with mutations in LTBP1,
although mice null for the long form of the gene (Ltbp1L/) die
shortly after birth from persistent truncus arteriosus (PTA) and
interrupted aortic arch (IAA), in association with aberrant cardiac
neural crest (CNC) development and decreased TGFb signaling.
Ltbp1L/ mice also show hypoplastic endocardial cushions in
early heart valve development, followed by hyperplastic valves in
late valvulogenesis, which appear to be the result of altered epithe-
lial-to-mesenchymal transition (EMT), a well-known TGFb-medi-
ated process [84].
Another group of ECM-associated proteins with clinical impor-
tance are members of the ADAMTS (a disintegrin-like and metal-
loprotease (reprolysin-type) with thrombospondin type 1 motif)
family. The ADAMTS superfamily includes 19 zinc metalloproteas-
es and 7 ADAMTS-like proteins that lack catalytic activity. While
many functions of family members have yet to be identiﬁed, re-
ports indicate involvement in maturation of procollagen and von
Willebrand factor, as well as in ECM turn over, including proteo-
lytic processing of proteoglycans and other ECM proteins. There
is strong evidence that they are also involved in TGFb sequestration
and activation. They appear to exert their effect on TGFb either di-
rectly via their interactions with LTBP1 (ADAMTSL2), or indirectly
by regulating microﬁbril formation through their interaction with
ﬁbrillin-1 (ADAMTS10, ADAMTSL2, 4, 6) and/or enhancing microﬁ-
bril biogenesis (ADAMTS10, ADAMTSL4, 6) [85,86].
Recessive forms of geophysic dysplasia (GD) are caused by
mutations in ADAMTSL2. GD patients have short stature, facial dys-
morphism, small hands and feet, thick skin, and progressive con-
tractures of the limb joints, which can often result in an irregular
gait. Importantly, these patients also suffer from progressive car-
diac valvular disease and tracheal stenosis, resulting in frequent
pulmonary infections and a high mortality rate. Dermal ﬁbroblasts
from GD patients with ADAMTSL2 mutations exhibit increased
TGFb secretion and SMAD2 activation [87]. Interestingly, dominant
forms of GD and of the related disease acromelic dysplasia (AD) are
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main 5 (TB5) of ﬁbrillin-1, suggesting that ADAMTSL2 may directly
interact with ﬁbrillin-1 in vivo. Microﬁbrillar network disorganiza-
tion and enhanced TGFb signaling have also been reported in ﬁbro-
blasts from patients with dominant forms of both GD and AD [88].
Analogous to the GD ﬁndings, mutations in genes encoding
ADAMTS proteins can cause recessive Weill-Marchesani syndrome
(WMS; ADAMTS10) [89] and recessive WMS-like syndrome (ADAM-
TS17), [90] while mutations in exons 9 and 41 of FBN1 can cause
dominant WMS [91]. Similarly, recessive forms of ectopia lentis
syndrome (ELS) are caused by mutations in ADAMTSL4 and ADAM-
TS17, [92] while mutations in FBN1 have been shown to cause
dominant ELS [93]. It remains to be determined whether WMS or
ELS are associated with aberrant TGFb signaling.
Mutations in a number of other ECM components have been
shown to cause aortic, skeletal, skin and/or ocular phenotypes that
share some degree of phenotypic overlap with MFS and related
conditions. Mutations in the gene encoding elastin (ELN) cause cu-
tis laxa with low penetrance ascending aortic aneurysm and dis-
section. Fibroblast cultures of patients with cutis laxa and aortic
aneurysm caused by ELN mutations have recently been found to
show impaired deposition of tropoelastin onto microﬁbril-contain-
ing ﬁbers, and enhanced tropoelastin coacervation and globule
formation, leading to lower amounts of mature, insoluble elastin.
They also displayed upregulated SMAD2 activation, implicating
increased TGFb signaling in disease pathogenesis [94].
Mutations in genes that encode collagen or inﬂuence itsmetabo-
lism can cause osteogenesis imperfecta (COL1A1, COL1A2), Ehlers–
Danlos syndrome (COL3A1, PLOD1), X-linked Allport syndrome
(COL4A5), hereditary angiopathy, nephropathy, muscle cramps and
aneurysm (COL4A1), and bone fragility with contractures, deafness
and arterial rupture (PLOD3), all ofwhich canbe associatedwith aor-
tic aneurysm (reviewed in [66]). However, the aortic involvement in
thesediseases is typicallyof lowpenetrance, and is highly variable in
both nature (i.e. progressive aneurysm without dissection, versus
sudden dissection with minimal dilatation) and distribution (i.e.
aortic root, ascending aorta, abdominal aorta or medium-sized
arteries). Furthermore, the degree to which TGFb signaling plays a
role in these phenotypes, if any, remains largely unknown.
9. Mutations in other cell membrane proteins result in altered
TGFb signaling
Mutations in other cell surface proteins also appear to affect
TGFb signaling and result in various phenotypes. Individuals with
autosomal recessive arterial tortuosity syndrome (ATS) show dif-
fuse and severe arterial tortuosity, as well as vascular stenoses,
segmental vascular hypoplasia and arterial aneurysms, in associa-
tion with disruption of elastic ﬁbers in the arterial wall. This disor-
der is caused by loss-of-function mutations in the SLC2A10 gene,
which encodes the glucose transporter type 10 membrane protein
(GLUT10) [95]. Interestingly, vascular tissue from ATS patients dis-
plays upregulated TGFb signaling, as evidenced by increased
SMAD2 activation and CTGF expression. The exact mechanism by
which this enhanced TGFb signaling occurs in ATS remains unclear,
although it may relate to impaired expression of the proteoglycan
decorin (an antagonist of TGFb superfamily signaling), which has
been shown in ﬁbroblasts cultured from ATS patients [95].
Mutations in other membrane proteins that can lead to altered
TGFb signaling also cause aneurysmal phenotypes. Mutations in
the genes encoding both endoglin (ENG) and activin receptor like
kinase 1 (ALK1), which cause hereditary hemorrhagic telangiecta-
sia (HHT) Type 1 and Type 2, respectively, occasionally present
with aortic andmedium-sized arterial aneurysms [96,97]. Endoglin
(also known as CD105) is expressed on the surface of endothelial
and hematopoietic cells and binds TGFb1 and TGFb3, in combina-tion with the TbRI/TbRII complex. Its expression increases during
angiogenesis, wound healing, and inﬂammation, all of which are
associated with increased TGFb signaling; hence it may serve to
facilitate or enhance TGFb-mediated downstream signaling events.
ALK1 is a type I TGFb receptor that appears to mediate TGFb1 sig-
naling in endothelial cells. More speciﬁcally, it binds to TGFb1 and
TbRII and inhibits TGFb1-dependent transcriptional activity of
TbRI. This suggests that the degree of binding of TGFb1 to either
ALK1 or TbRI may inﬂuence downstream signaling readout. Inter-
estingly, mice homozygous for nonsense mutations in either Eng
or Alk1 show remarkable phenotypic overlap to Tgfbr1 and Tgfbr2
knockout mice [98,99]. It remains to be determined how ENG
and ALK1 mutations cause aneurysmal disease, and what effect
they have on the modulation of the different TGFb-dependent
intracellular signaling cascades.
10. Mutations in the cellular contractile apparatus result in
altered TGFb signaling
In addition to ECM-mediated alterations in the contractile appa-
ratus of cells (e.g. during the transformation from ﬁbroblasts to
myoﬁbroblasts), recent work identifying genes causing iFTAA has
implicated perturbation of the vascular contractile apparatus in
aneurysm pathogenesis. Heterozygous mutations inMYH11, which
encodes smooth muscle myosin heavy chain 11 (MYH11), can
cause iFTAA in association with patent ductus arteriosus (PDA)
and rarely bicuspid aortic valve (BAV) [100,101]. Heterozygous
mutations in ACTA2, which encodes aSMA, have been found to
cause ascending aortic aneurysm and dissection, that can be found
in association with descending aortic aneurysm and dissection,
PDA and BAV [102]. Some patients show a lattice-like purplish dis-
coloration of the skin, caused by dilatation of medium sized veins
(livedo reticularis), as well as pigmented cysts of the iris (iris ﬂoc-
culi). As the number of documented mutations in these two genes
has increased, it has become apparent that the resulting pheno-
types are highly variable, with manifestations occurring at all ages
and in tissues outside of the cardiovascular system [103,104].
Most recently, heterozygous mutations in MYLK1, the kinase
that controls SMC contractile function, have been identiﬁed in 2
families who demonstrated acute aortic dissection with little to
no enlargement of the aorta [105]. The nature of the mutations
identiﬁed in MYH11 and ACTA2 indicate that they impair protein
assembly and act in a dominant negative manner. By contrast,
the mutations in MYLK1 identiﬁed so far result in impaired
calmodulin binding or kinase activity. In combination with the
observation of aortic medial degeneration in mice possessing
VSMC-speciﬁc knockdown of Mylk, these data implicate loss of
function as the mechanistic basis of MYLK1 mutations.
While initial studies of VSMCs isolated from patients with
MYH11 mutations showed upregulation of proliferation, insulin-
like growth factor 1 (IGF-1) signaling, and components of the
ANG-II signaling cascade, they failed to ﬁnd evidence of increased
TGFb signaling [101]. More recent work using aortic tissue from
patients harboring MYH11 mutations has found evidence of high
VSMC expression of the calcium-binding protein S100A12, a pro-
tein which has been associated with high TGFb expression and sig-
naling in mice [106]. Furthermore, increased SMAD activation and
CTGF expression has implicated high TGFb signaling in aortic tissue
from patients with missense ACTA2 mutations [107].
The mechanism by which mutations in genes encoding or inﬂu-
encing the intracellular contractile apparatus cause aberrant acti-
vation of extracellularly-sequestered TGFb remains to be
determined. Binding and contractility of intracellular cytoskeletal
components (such as actin and myosin) via membrane-embedded
integrins is required to permit dimerization of extracellular
ﬁbronectin and formation of a stable insoluble ﬁbrillar matrix
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microﬁbrils, [109] as well as incorporation of the LLC into microﬁ-
brils [110,111]. One hypothesis posits that mutations in genes that
affect the structure or function of intracellular cytoskeletal pro-
teins may prevent correct ﬁbronectin assembly, leading to defec-
tive ﬁbrillin-1 incorporation into microﬁbrils and reduced
sequestration of latent TGFb. This may leave it more prone to acti-
vation, resulting in enhanced TGFb signaling [107]. Alternatively,
TGFb signaling can also be inﬂuenced by the cytoskeleton through
alterations in the trafﬁcking and/or activity of TGFb receptors and
intracellular signaling intermediates (reviewed in [112]).
Finally, the large actin-binding protein ﬁlamin-A, encoded by
the FLNA gene on the X-chromosome, is another cytoskeletal (but
non-contractile) intracellular protein that has been implicated in
aortic aneurysm disease and shows connection to TGFb signaling.
A small subset of women with the neurological disease periventric-
ular nodular heterotopia (PVNH), in which ﬁlamin-A expression or
function is altered, show a predisposition for aneurysm, usually inTable 1
Diseases caused by germline mutations in components of the ECM and TGFb signaling cas
Gene (exons) Protein (speciﬁc domains) Clinical Syndrome
Extracellular proteins
FBN1 Fibrillin-1 Marfan syndrome
Ectopia lentis syndrome (dom
FBN1 (9, 41) Weill-Marchesani syndrome
FBN1 (38) Fibrillin-1 (TB4 domain) Stiff skin syndrome
FBN1 (41, 42) Fibrillin-1 (TB5 domain) Geophysic dysplasia (domina
Acromelic dysplasia (domina
FBN2 Fibril lin-2 Congenital contractural arac
EFEMP2 Fibulin-4 Cutis laxa (recessive) with ar
and aortic aneurysm
FBLN5 Fibulin-5 Cutis laxa (recessive) with ar
but no aneurysm
Age-related macular degener
ELN Elastin Cutis laxa, low penetrance a
LTBP2 Latent TGFb binding protein 2 Primary congenital glaucoma
Microspherophakia
LTBP3 Latent TGFb binding protein 3 Altered permanent teeth and
LTBP4 Latent TGFb binding protein 4 Urban-Rifkin-Davis syndrom
ADAMTS10 ADAMTS protein 10 Weill-Marchesani syndrome
ADAMTS17 ADAMTS protein 17 Weill-Marchesani-like syndr
Ectopia lentis syndrome (rec
ADAMTSL2 ADAMTS-like protein 2 Geophysic dysplasia (recessi
Transmembrane proteins
TGFbR1 TGFb receptor type 1 Loeys Dietz syndrome
Isolated familial thoracic aor
TGFbR2 TGFb receptor type 2 Loeys Dietz syndrome
Isolated familial thoracic aor
ENG Endoglin Hereditary hemorrhagic tela
ACVRL1 Activin receptor-like kinase I Hereditary hemorrhagic tela
SLC2A10 Glucose transporter type 10 Arterial tortuosity syndrome
Intracellular proteins
SMAD3 SMAD3 Loeys Dietz syndrome with o
Isolated familial thoracic aor
SMAD4 SMAD4 Loeys Dietz syndrome with m
disease and juvenile polypos
ACTA2 a-Smooth muscle actin Isolated familial thoracic aor
descending aortic aneurysm,
arteriosus and bicuspid aorti
MYH11 Smooth muscle myosin Isolated familial thoracic aor
patent ductus arteriosus, bic
MYLK1 Myosin light chain kinase Aortic dissection without pri
FLNA Filamin-A Periventricular nodular heter
aortic aneurysm and valvula
PTPN11 Protein-tyrosine phosphatase 2C Noonan and LEOPARD syndr
NF1 Neuroﬁbromin-1 Neuroﬁbromatosis Type 1association with other systemic connective tissue ﬁndings [113].
Mutations in FLNA have also been implicated in myxomatous valve
disease, a phenotype commonly seen in MFS and LDS. Filamin-A
can function as a positive regulator of TGFb signaling throughmod-
ulation of RhoA and SMAD trafﬁcking, as well as contributing to the
negative regulation of both ERK1/2 and MMP signaling via a
RAS-GRF1 dependent mechanism [114,115].
11. Controversy surrounding the role of TGFb signaling in
cardiovascular disease states
While there is considerable evidence linking high TGFb signal-
ing to aneurysmal disease states, conﬂicting data exists. For exam-
ple, juvenile Emilin1-knockout mice display a diffusely small
vasculature and hypertension, despite high TGFb signaling [116].
However, given the apparently paradoxical signaling that occurs
with TGFbRI/II, SMAD3 and SMAD4 mutations, the precise vascular
distribution and developmental timing of high TGFb signaling incade.
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2012 J.J. Doyle et al. / FEBS Letters 586 (2012) 2003–2015these animals may need closer scrutiny. Other work has shown
that VSMC-speciﬁc elimination of TGFb signaling in the ascending
aorta of fetal mice results in PTA, impaired elastogenesis and vessel
widening, [117] while VSMC-speciﬁc elimination of Tgfbr2 results
in impaired elastogenesis in the descending aorta [118].
Non-genetic models of vascular disease have also raised ques-
tions about the exact role that TGFb signaling plays in aneurysmal
disease. It is well known that ANG-II signaling through the AT1R
can enhance TGFb signaling, by inducing the expression of TGFb li-
gands, receptors and activators. ANG-II can also activate SMAD and
MAPK signaling cascades in VSMCs independently of TGFb [119].
TGFb NAb treatment appears to induce Ang-II infusion-mediated
aneurysms in normocholesterolemic C57BL/6 mice, a mouse strain
that does not typically incur prominent aneurysmal disease from
Ang-II infusion [120]. The lesions were inﬂammatory in nature,
and the incidence of aneurysm and dissection was ameliorated
by monocyte depletion, suggesting that TGFb may be protective
speciﬁcally within the setting of acute and intense inﬂammation.
By contrast, increased adventitial interleukin-6 (IL-6) expres-
sion has been observed at sites of dissection in human aneurysms.
Increased expression of IL-6, monocyte chemoattractant protein-1
(MCP-1) and its receptor (CCR2) have also been shown in models of
Ang-II-induced aneurysm, with CCR2 signaling contributing to IL-6
expression. Interestingly, within the setting of Ang-II infusion,
CCR2-positive macrophages accumulate in the adventitia, speciﬁ-
cally at sites of aneurysm and most prominently at sites of dissec-
tion [121]. Furthermore, mice lacking Ccr2 show reduced
macrophage accumulation, decreased IL-6 and Mcp-1 expression,
and protection from early dissection in response to Ang-II infusion
(although they still undergo dissection after chronic infusion).
TGFb has a number of anti-inﬂammatory properties, and is known
to induce the expression of both IL-6 and MCP-1 in many cell types,
including ﬁbroblasts and VSMCs. Furthermore, TGFb can positively
regulate monocyte recruitment and macrophage differentiation,
[122] while JNK1 signaling suppresses LOX, which normally nega-
tively regulates MCP-1 expression [123]. Administration of TGFb
NAb has even been shown to provide signiﬁcant protection from
Ang-II induced inﬂammatory aneurysms after targeted silencing
of Cxcl10, a known chemoattractant for monocytes and macro-
phages [124]. Therefore it remains unclear exactly what role TGFb
plays in Ang-II mediated aneurysm development and how this re-
lates to human disease.
This complexity concerning the role of TGFb in aneurysmal dis-
ease is closely mirrored by that observed in another cardiovascular
disease state, namely cardiomyopathy (reviewed in [125]). Again,
the data elucidating the exact role that TGFb plays in this disease
state are conﬂicting. On the one hand, spontaneous cardiac hyper-
trophy and interstitial ﬁbrosis develop in Tfgb1-overexpressing
mice [126]. Furthermore, mice haploinsufﬁcient for Tgfb1 are pro-
tected from age-related cardiac ﬁbrosis and diastolic dysfunction,
[127] while losartan treatment ameliorates genetically-inherited
ﬁbrosis and cardiac failure in dystrophin-deﬁcient mdxmice [128].
TGFb antagonism can also attenuate inﬂammatory-
associated cardiacﬁbrosis causedby cardiac-speciﬁc tumornecrosis
factor alpha (TNFa) overexpression [129]. Similarly, TGFbNAb treat-
ment prevents collagen accumulation and attenuates diastolic dys-
function without affecting cardiac hypertrophy in pressure
overload-induced cardiomyopathy [130]. Finally, treatment with
theARB telmisartanhasbeen shown to lead to a signiﬁcant improve-
ment in cardiac hypertrophy, ﬁbrosis and left ventricular function in
rats after experimental autoimmunemyocarditis (EAM)-induceddi-
lated cardiomyopathy, in association with reduced TGFb1, Mmp2
and 9, collagen I and III, IL-6, IL-1 and Mcp1 expression [131].
However, there are conﬂicting results. For example, inhibition
of TGFb signaling using mice overexpressing an inducible domi-
nant-negative form of Tgfbr2 show reduced collagen deposition,increased left ventricular dilation and systolic dysfunction in pres-
sure-overload induced cardiomyopathy [132]. Hence it may be the
magnitude or timing of TGFb activation that is key to determining
whether it plays a protective or deleterious role in disease progres-
sion. For example, basal TGFb activity may be necessary to preserve
cardiac structure and to protect the myocardium from uncon-
trolled ECM degradation that could lead to cardiac dilation; on
the other hand excessive TGFb activation may be deleterious due
to the promotion of collagen deposition, increased myocardial stiff-
ness and ultimately diastolic dysfunction.
In summary, much progress has been made in our understand-
ing of TGFb-related vasculopathies (summarized in Table 1). This
has led to the development of a number of potential novel thera-
peutic strategies, several of which are clinically available and are
now entering human trials. Notwithstanding this, many questions
remain unresolved, highlighting the need to carefully consider con-
text when developing pathogenic and therapeutic hypotheses, and
to utilize model systems that adequately recapitulate the physio-
logic complexity of the human system.
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